CF
RVNC

Centaurus Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

Centaurus Financial’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,612
Closed -$155K – 866
2023
Q4 		$155K Sell
17,612
-6,915
-28% -$56.7K 0.01% 649
2023
Q3 		$281K Buy
24,527
+7,242
+42% +$139K 0.02% 484
2023
Q2 		$437K Buy
17,285
+1,404
+9% +$43.7K 0.04% 385
2023
Q1 		$512K Buy
15,881
+688
+5% +$21.4K 0.04% 387
2022
Q4 		$280K Sell
15,193
-1,217
-7% -$27.8K 0.03% 509
2022
Q3 		$443K Sell
16,410
-3,838
-19% -$77.9K 0.04% 371
2022
Q2 		$280K Sell
20,248
-442
-2% -$6.8K 0.03% 511
2022
Q1 		$403K Sell
20,690
-188
-0.9% -$2.85K 0.03% 469
2021
Q4 		$341K Sell
20,878
-30,342
-59% -$506K 0.03% 543
2021
Q3 		$1.43M Buy
51,220
+1,403
+3% +$40K 0.12% 205
2021
Q2 		$1.48M Sell
49,817
-760
-2% -$21.9K 0.12% 198
2021
Q1 		$1.41M Sell
50,577
-3,262
-6% -$90.2K 0.14% 175
2020
Q4 		$1.53M Sell
53,839
-7,075
-12% -$183K 0.16% 158
2020
Q3 		$1.53M Buy
+60,914
New +$1.6M 0.21% 112

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Centaurus Financial's RVNC Position: Q1 2024 in Review

Centaurus Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 17,612 shares — an estimated $155K sold.

Centaurus Financial first reported a position in RVNC in Q3 2020 and held it in 14 quarters. The position peaked at $1.53M in Q3 2020. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

  • Centaurus Financial reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
  • Centaurus Financial sold 17,612 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $155K.
  • Centaurus Financial first reported a position in Revance Therapeutics, Inc. in Q3 2020 and held it in 14 quarters.
  • Centaurus Financial's Revance Therapeutics, Inc. position peaked at $1.53M in Q3 2020.
  • 188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Centaurus Financial's 13F filing for Q1 2024, filed 14 May 2024.